The Role of Nurses in Video-Based Communication to Reduce Loneliness in Intensive Care Unit Patients (VBC-ICU)

July 8, 2025 updated by: Universitas Padjadjaran

The Effect of Video-Based Communication on Reducing Loneliness in Intensive Care Unit Patients: A Quasi-Experimental Study

This study aims to evaluate the effectiveness of video-based communication in reducing loneliness among intensive care unit (ICU) patients at Dr. Hasan Sadikin General Hospital in Bandung, Indonesia. ICU patients often experience psychological distress, particularly loneliness, due to restricted family visits and physical isolation.

A quasi-experimental design with a pre-test and post-test control group is used, involving 36 participants who are randomly assigned to either the intervention or control group. The intervention group receives structured video-based communication with family members for three consecutive days, with each session lasting between 5 to 20 minutes. Nurses facilitate the intervention by ensuring patient safety, providing emotional support, and assisting with the communication process. The control group receives standard ICU care without the communication intervention.

Loneliness levels are assessed using the De Jong Gierveld Loneliness Scale (DJGLS) before and after the intervention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study investigates the effectiveness of video-based communication in reducing loneliness among patients in the Intensive Care Unit (ICU). Loneliness is a common psychosocial issue in ICU patients, caused by physical isolation, limited visitation policies, and minimal social interaction. It is associated with increased stress, potential suppression of immune response, and extended hospitalization. The intervention provides a practical approach by enabling virtual interaction with family members, allowing emotional connection despite physical distance.

The study uses a quasi-experimental design with a pre-test and post-test control group. A total of 36 patients are recruited from Dr. Hasan Sadikin General Hospital in Bandung and randomly assigned to either an intervention or control group. The intervention group receives structured video-based communication using WhatsApp for three consecutive days, with each session lasting between 5 and 20 minutes. The control group receives standard ICU care without the additional communication support. The De Jong Gierveld Loneliness Scale (DJGLS) is used to assess emotional and social loneliness levels before and after the intervention.

Nurses act as primary facilitators in the intervention. Their responsibilities include ensuring clinical stability, setting up the communication devices, emotionally supporting patients during the sessions, monitoring patient responses, documenting the process, and coordinating communication with family members.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Indonesia
    • Jawa Barat
      • Bandung, Jawa Barat, Indonesia, 40161
        • dr. Hasan Sadikin General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Patients admitted to the intensive care unit (ICU)
  2. Patients aged over 18 years with a minimum of 72 hours of care in the ICU
  3. Patients who are able to understand and communicate in the Indonesian language

Exclusion Criteria:

  1. Patients with medical conditions such as decreased consciousness, total blindness, or severe neurological disorders
  2. Patients with a history of psychiatric disorders

Drop Out:

  1. Patients who are discharged from the ICU of Dr. Hasan Sadikin General Hospital during the study period will be considered drop-outs
  2. Patients whose health deteriorates to the extent that they are unable to continue participation in the study
  3. Patients who die during the study period
  4. Patients who are transferred from the ICU to general inpatient wards

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Intervention Group - Video-based Communication
Participants in this group received structured video-based communication with their family members using WhatsApp. Each session lasted 5-20 minutes and was conducted once daily for three consecutive days. The communication was facilitated by a nurse and included positive messages, emotional support, and discussion of future plans. The aim was to reduce emotional and social loneliness in ICU patients.
Behavioral: Video-based Communication
Participants received structured video-based communication sessions with their family members using the WhatsApp platform. The intervention was delivered once daily for three consecutive days, with each session lasting between 5 and 20 minutes. Communication was guided to include emotional support, positive conversations, and future-oriented discussion. The sessions were facilitated by nurses who ensured clinical stability, technical setup, and emotional readiness of the patient. This intervention aimed to reduce emotional and social loneliness among ICU patients and was integrated into standard intensive care routines without disrupting medical care.
No Intervention: Control Group - Standard ICU Care
Participants in this group received standard ICU care without any video-based communication intervention. They continued with routine treatment and monitoring in the ICU setting for the duration of the study period. This group was used as a comparison to assess the impact of video-based communication on loneliness levels.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Loneliness Score (De Jong Gierveld Loneliness Scale)
Time Frame: Baseline (Day 1) to Post-Intervention (Day 3)
This outcome measures the change in loneliness among ICU patients before and after the intervention, using the De Jong Gierveld Loneliness Scale (DJGLS). The scale assesses both emotional and social loneliness with 11 items, validated in Indonesian. Higher scores indicate greater loneliness. The score is recorded at baseline (pre-intervention) and after 3 days of intervention (post-test). The difference in mean scores is used to assess effectiveness.
Baseline (Day 1) to Post-Intervention (Day 3)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Universitas Padjadjaran

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Cecep Eli Kosasih, S.Kp., MNS., Ph.D, Universitas Padjadjaran
  • Study Director: Ristina Mirwanti, S.Kep., Ners., M.Kep., Universitas Padjadjaran

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 24, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 24, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 24, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 29, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 8, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 18, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 18, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 8, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NURS-202506.01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Loneliness

Clinical Trials on Video-based Communication

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings